IonOpticks responds to growing global market
needs for proteomics tools by partnering with Nordic private equity
firm
MELBOURNE, Australia and
STOCKHOLM, Sept. 10, 2024 /PRNewswire/ -- IonOpticks, a
leading global producer of high-performance chromatography columns,
announces its partnership with Adelis Equity Partners ("Adelis").
The Nordic private equity firm is renowned for partnering with and
accelerating the growth of companies in their focus sectors
including healthcare and life sciences. The investment from Adelis
will augment IonOpticks' global presence and drive innovation as
the company expands closer to key markets and consolidates its
leading position in the exciting and rapidly growing field of
proteomics and adjacent applications.
The strategic partnership will enable IonOpticks to scale its
operations globally, enhancing product development and better
positioning the company to serve its growing customer base. Being
closer to its customers and collaborators while also ensuring
compatibility across major LC-MS platforms is a key priority,
allowing researchers worldwide to benefit from IonOpticks'
class-leading chromatography. Adelis' extensive experience,
industrial advisor network and resources will support IonOpticks in
maintaining its position as the provider of the best solutions for
LC-MS proteomics research.
IonOpticks also strengthens its board with the appointment of
several industry heavyweights, including Dr. Peter Wrighton-Smith as Chairman. With an
established career in scaling life sciences companies, Peter is
well-positioned to guide IonOpticks through its next phase of
growth. Joining founders Xavier Perronnet and Dr. Jarrod Sandow, the board also welcomes industry
leaders Mårten Winge, Sibel Arnes,
and Rasmus Molander.
"I'm excited to join IonOpticks to help support the expansion
of its commercialisation efforts globally and to help the company
with its ambitious program of new product introductions into
current and new markets." Dr. Peter
Wrighton-Smith, newly appointed Chairman of IonOpticks,
explains.
"We chose to partner with Adelis because they share our
vision for IonOpticks' goals and are a strong cultural fit. Their
genuine desire to work with us and guide the company to realise its
goals, together with their experience, networks, and resources,
made them the ideal partner. This partnership allows us to continue
developing the best chromatography solutions for researchers
worldwide and pursue further innovations tailored to the industry's
evolving needs," says Xavier Perronnet, Chief Executive
Officer of IonOpticks.
"Ultimately, it's about human health, and we believe that
maximising what is discoverable in biological samples is a vital
early step in developing therapies and improving patient outcomes.
That's what IonOpticks does," Perronnet continues.
Director Sibel Arnes and
Co-managing Partner Rasmus Molander at Adelis note,
"Europe and indeed the Nordics
has a long legacy in proteomics and pioneering human health
research. When we met the team, we immediately recognised
IonOpticks' unique solutions and global potential. Their commitment
to working with key opinion leaders in the field and delivering
best-in-class solutions is impressive, and the results from the
accelerating research in proteomics is promising. IonOpticks aligns
perfectly with Adelis' strategy of supporting unique and growing
companies in healthcare and life sciences. It is a privilege to
partner with a company that can meaningfully contribute to
addressing many of our currently unresolved health conditions, and
we look forward to collaborating with the IonOpticks team in the
coming years."
IonOpticks' technology was developed at WEHI (Walter and Eliza
Hall Institute of Medical Research) and the company was incubated
at the institute for two years. "IonOpticks' evolution from its
early-stage research and development to a global market presence,
and now through this strategic partnership, underscores the value
of supporting entrepreneurial scientists alongside executive
leadership. It highlights the incredible potential of Australian
life sciences innovations when backed by robust incubation and
support," says Dr. Anne-Laure
Puaux, Head of Business Development at WEHI.
About IonOpticks:
IonOpticks produces high-performance chromatography solutions
for the global research community enhancing mass spectrometry
(LC-MS) and high-end proteomics research. Their solutions enhance
the sensitivity of mass spectrometry sample analysis, enabling
scientists and clinicians to discover more from their samples.
These advancements are valuable for a broad range of applications
within the field of biological and medical research including drug
discovery, phosphoproteomics and shotgun proteomics.
https://ionopticks.com/
About Adelis Equity Partners
Adelis is a growth partner for well-positioned companies
primarily in the Nordic and DACH regions. Adelis partners with
management and/or owners to build businesses in growth segments
with strong market positions. Since raising its first fund in 2013,
Adelis has been one of the most active investors in the Nordic
middle-market, making 42 platform investments and more than 230
add-on acquisitions. Adelis manages approximately €3.0 billion in
capital. For more information, please
visit www.adelisequity.com.
Photo -
https://mma.prnewswire.com/media/2500040/IonOpticks__Board_Directors_L_R_M_rten_Winge_Sibel_Arnes_Xavier_Perronnet.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/ionopticks-partners-with-adelis-to-accelerate-global-expansion-and-innovation-302242743.html